Literature DB >> 33511969

Traditional Chinese medicine (TCM) as a source of new anticancer drugs.

Chang-Liang Yao1, Jian-Qing Zhang1, Jia-Yuan Li1, Wen-Long Wei1, Shi-Fei Wu1, De-An Guo1.   

Abstract

Covering: up to July 2020Drugs derived from traditional Chinese medicine (TCM) include both single chemical entities and multi-component preparations. Drugs of both types play a significant role in the healthcare system in China, but are not well-known outside China. The research and development process, the molecular mechanisms of action, and the clinical evaluation associated with some exemplificative anticancer drugs based on TCM are discussed, along with their potential of integration in western medicine.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33511969     DOI： 10.1039/d0np00057d

Source DB:  PubMed          Journal:  Nat Prod Rep        ISSN： 0265-0568            Impact factor:   13.423


  13 in total

Review 1.  Genus Sophora: a comprehensive review on secondary chemical metabolites and their biological aspects from past achievements to future perspectives.

Authors:  Howaida I Abd-Alla; Dalila Souguir; Mohamed O Radwan
Journal:  Arch Pharm Res       Date:  2021-12-15       Impact factor: 4.946

2.  Photoaffinity Probe Reveals the Potential Target of Harringtonolide for Cancer Cell Migration Inhibition.

Authors:  Tian-Yu Zhu; Xiu-Tao Wu; Chen Chen; Xiao-Qin Liu; Li Zhu; Jian-Guang Luo; Ling-Yi Kong
Journal:  ACS Med Chem Lett       Date:  2022-02-02       Impact factor: 4.345

3.  Alizarin, a nature compound, inhibits the growth of pancreatic cancer cells by abrogating NF-κB activation.

Authors:  Zihang Xu; Yifei Hou; Chunpu Zou; Haibin Liang; Jiasheng Mu; Xiaoning Jiao; Yangzhuangzhuang Zhu; Lin Su; Mingxi Liu; Xiao Chen; Chunmei Qian; Xiandan Zhu; Wei Gong; Qian Dong; Fei Zhang
Journal:  Int J Biol Sci       Date:  2022-03-28       Impact factor: 10.750

4.  A Strategy for Screening the Lipid-Lowering Components in Alismatis Rhizoma Decoction Based on Spectrum-Effect Analysis.

Authors:  Xiao-Yan Chang; Jia-Shuo Wu; Fang-Qing Zhang; Zhuang-Zhuang Li; Wei-Yi Jin; Jing-Xun Wang; Wei-Hua Wang; Yue Shi
Journal:  J Anal Methods Chem       Date:  2022-01-04       Impact factor: 2.193

5.  The Synergistic Reducing Drug Resistance Effect of Cisplatin and Ursolic Acid on Osteosarcoma through a Multistep Mechanism Involving Ferritinophagy.

Authors:  Zhen Tang; Hui Dong; Tian Li; Ning Wang; Xinghui Wei; Hao Wu; Yichao Liu; Wei Wang; Zheng Guo; Xin Xiao
Journal:  Oxid Med Cell Longev       Date:  2021-12-21       Impact factor: 6.543

6.  Xanthatin Selectively Targets Retinoblastoma by Inhibiting the PLK1-Mediated Cell Cycle.

Authors:  Jie Yang; Yongyun Li; Chunyan Zong; Qianqian Zhang; Shengfang Ge; Lei Ma; Jiayan Fan; Jianming Zhang; Renbing Jia
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-12-01       Impact factor: 4.799

7.  Integrating Network Pharmacology and Experimental Verification to Explore the Mechanism of Effect of Zuojin Pills in Pancreatic Cancer Treatment.

Authors:  Kunpeng Wang; Xiongying Miao; Fanhua Kong; Siqi Huang; Jinggang Mo; Chong Jin; Yanwen Zheng
Journal:  Drug Des Devel Ther       Date:  2021-09-04       Impact factor: 4.162

8.  Asymmetric total synthesis of (1S,2S,4S)-β-elemene.

Authors:  Wei Chen; Zhun Feng; Qiang Liu
Journal:  RSC Adv       Date:  2022-03-15       Impact factor: 3.361

9.  Maackiain Modulates miR-374a/GADD45A Axis to Inhibit Triple-Negative Breast Cancer Initiation and Progression.

Authors:  Fu Peng; Li Wang; Liang Xiong; Hailin Tang; Junrong Du; Cheng Peng
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

10.  Structurally diverse diterpenoid alkaloids from the lateral roots of Aconitum carmichaelii Debx. and their anti-tumor activities based on in vitro systematic evaluation and network pharmacology analysis.

Authors:  Yang Yu; Shifei Wu; Jianqing Zhang; Jiayuan Li; Changliang Yao; Wenyong Wu; Yingying Wang; Hongjian Ji; Wenlong Wei; Min Gao; Yun Li; Shuai Yao; Yong Huang; Qirui Bi; Hua Qu; De-An Guo
Journal:  RSC Adv       Date:  2021-08-04       Impact factor: 4.036
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.